Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery.
ribociclib in combination with an aromatase inhibitor for adult patients with HR-positive, HER2-negative stages II and III breast cancer at high-risk for recurrence following surgery.
There's no such restriction for the new ribociclib indication, which"allows us to offer treatment with a CDK4/6 inhibitor to a significantly broader group of people," lead investigatorThe new indication joins ribociclib's previous approval for advanced or metastatic hormone receptor -positive, human epidermal growth factor receptor 2 -negative breast cancer in combination with an aromatase inhibitor or fulvestrant.
Invasive disease-free survival at 36 months was 90.7% in the ribociclib arm vs 87.6% with aromatase inhibitor monotherapy , the ribociclib group continued to do better, with an invasive disease-free survival rate of 88.5% vs 83.6% in the control arm.
Malignant Breast Neoplasm Breast Carcinoma HER2 Negative Breast Cancer HER2- Breast Cancer Aromatase Inhibitor Exemestane Breast Mammary Gland Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Genomics Genomic Medicine Lymph Nodes Surgery Hepatic Surgery Liver Surgery Epidermal Growth Factor Receptor EGFR - Epidermal Growth Factor Receptor EGFR Receptors
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer IndicationsSubcutaneous injections save time, taking about 7 minutes, vs 30-60 minutes for intravenous infusion.
Read more »
Adjuvant Atezolizumab Plus Bevacizumab Strike Out in HCCPromising initial results from the IMBRAVE050 trial fell through after longer follow-up.
Read more »
Adjuvant Aspirin Trial in CRC InconclusiveInvestigators compared outcomes between patients with stage II/III colon cancer given adjuvant aspirin and those given placebo.
Read more »
No DFS Benefit With Adjuvant Durvalumab in Early NSCLCThe lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in the CCTG BR.31 trial underscores the need to identify biomarkers.
Read more »
Adjuvant Pembrolizumab in Endometrial Cancer: 'Disappointing' Yet 'Game-Changing'Adding adjuvant pembrolizumab to chemotherapy only led to a benefit in patients with mismatch repair-deficient high-risk endometrial cancers, a phase 3 trial found.
Read more »
Should All Patients With Early Breast Cancer Receive Adjuvant Radiotherapy?Researchers analyzed data from patients with early breast cancer who were randomized to receive high-dose or no radiotherapy.
Read more »